Gregory Y. H. Lip MD, FRCP, DFM, FACC, FESCPrice-Evans Chair of Cardiovascular Medicine, University of Liverpool and Director, Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Distinguished Professor in Cardiovascular Sciences, Aalborg University, Aalborg, Denmark; Adjunct Professor, Yonsei University, Seoul, Korea
Professor Lip, MD, is Price-Evans Chair of Cardiovascular Medicine, at the University of Liverpool, UK – and Director of the Liverpool Centre for Cardiovascular Science at the University of Liverpool and Liverpool Heart & Chest Hospital. He is also Distinguished Professor at Aalborg University, Denmark; and Adjunct Professor, Yonsei University, Seoul, Korea. He is also Visiting Professor in the School of Life & Health Sciences at the University of Aston in Birmingham, England; Adjunct Professor of Cardiovascular Sciences, Aalborg University, Denmark; and Visiting Professor of Cardiology, Belgrade University, Serbia.
Half of his time is spent as a clinical cardiologist, and he practises the full range of cardiovascular medicine, including outpatient clinics, with large atrial fibrillation and hypertension specialist clinics, and coronary care unit duties. He also undertakes coronary intervention and participates in a 24/7 primary angioplasty rota for ST elevation MIs.
Professor Lip has had a major interest into the epidemiology of AF, as well as the pathophysiology of thromboembolism in this arrhythmia. Furthermore, he has been researching stroke and bleeding risk factors, and improvements in clinical risk stratification. The CHA2DS2-VASc and HAS-BLED scores - for assessing stroke and bleeding risk, respectively – were first proposed and independently validated following his research, and are now incorporated into international guidelines. He was selected to the Thomson Reuters Science Watch list of “Who and What was Hot in Scientific Reseach in 2012” (issued June 2013) which lists the most influential scientific researchers and research papers of the year [http://sciencewatch.com/articles/hottest-research-2012]. In 2014, Professor Lip was ranked by Expertscape as the world's leading expert in the understanding and treatment of AF, and correspondingly, the University of Birmingham listed as the world's top institution for AF research [http://www.prlog.org/12273752-expertscape-ranks-top-doctors-and-hospitals-in-atrial-fibrillation.html].
Professor Lip is a member of the European Heart Rhythm Association (EHRA) and is Chairman of its scientific documents committee (2013-), and serves on the board of the Working Group on Thrombosis of the European Society of Cardiology (ESC).
Professor Lip has acted as Clinical Adviser for the UK National Institute for Health & Clinical Excellence (NICE) guidelines on atrial fibrillation (AF) management. He was on the writing committee for the 8th American College of Chest Physicians (ACCP) Antithrombotic Therapy Guidelines for Atrial Fibrillation, as well as various guidelines and/or position statements from EHRA. He was also on the writing committees of the 2010 ESC Guidelines on Atrial Fibrillation, the 2012 ESC Focussed Update Guidelines on Atrial Fibrillation, the 2012 ESC Guidelines on Heart Failure, and the 2014 NICE guidelines on AF. He was Deputy Editor (“content expert”) for the 9th ACCP guidelines on antithrombotic therapy for AF (2012).
Professor Lip has acted as Senior Editor for major international textbooks [eg, Lip GYH, Hall JE (eds) Comprehensive Hypertension. Mosby] and Section Editor on hypertension (eg, Crawford, DiMarco, Paulus Cardiology, now in 3rd edition), as well as contributed to major textbooks [eg, the European Textbook of Cardiovascular Medicine (chapter on atrial fibrillation that serves as the core curriculum for ESC cardiology trainees), and Crawford’s Cardiology textbook chapter on atrial fibrillation, etc. Professor Lip is involved at the senior editorial level for major international journals, including Thrombosis & Haemostasis (Editor-in-Chief, Clinical Studies); Europace (Associate Editor); and Circulation (Guest Editor).
Recent Contributions to PracticeUpdate:
- Stroke and Bleeding Risk in Patients With Atrial Fibrillation and a CHA2DS2-VASc Risk Score of 1
- Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With AF and Severe CKD
- Systematic AF Screening According to NT-proBNP Level
- Apixaban vs Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease
- Comparing Antithrombotic Therapies After ACS or PCI in Patients With AF and Prior Stroke
- Tranexamic Acid in Patients Undergoing Noncardiac Surgery
- Diabetes-Related Complications and Mortality in Patients With AF Receiving Oral Anticoagulants
- Ciraparantag Reverses Apixaban and Rivaroxaban Activity in Healthy Older People
- Early Rhythm Control Therapy in Patients With AF and HF
- Lower Risk of Stroke After Alcohol Abstinence in Patients With Incident Atrial Fibrillation